Ken Griffin Guardant Health, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$22.3 - $36.29 $548,580 - $892,734	24,600 Added 37.16%	90,800 $2.08 Million
Q2 2024 Aug 14, 2024	SELL	$16.07 - $31.84 $13.1 Million - $25.9 Million	-814,600 Reduced 92.48%	66,200 $1.91 Million
Q1 2024 May 15, 2024	BUY	$17.13 - $26.91 $13.9 Million - $21.8 Million	810,100 Added 1145.83%	880,800 $18.2 Million
Q4 2023 Feb 14, 2024	BUY	$21.58 - $29.5 $401,387 - $548,700	18,600 Added 35.7%	70,700 $1.91 Million
Q3 2023 Nov 14, 2023	BUY	$25.8 - $39.97 $170,280 - $263,802	6,600 Added 14.51%	52,100 $1.54 Million
Q2 2023 Aug 14, 2023	SELL	$20.94 - $38.01 $766,404 - $1.39 Million	-36,600 Reduced 44.58%	45,500 $1.63 Million
Q1 2023 May 15, 2023	SELL	$22.92 - $33.76 $2.89 Million - $4.26 Million	-126,200 Reduced 60.59%	82,100 $1.92 Million
Q4 2022 Feb 14, 2023	SELL	$25.44 - $59.78 $5.8 Million - $13.6 Million	-228,000 Reduced 52.26%	208,300 $5.67 Million
Q3 2022 Nov 14, 2022	BUY	$43.66 - $61.0 $5.04 Million - $7.04 Million	115,400 Added 35.96%	436,300 $23.5 Million

323

127M

844K

2.38M

Ticker GH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 102,220,000
Market Cap $3.34B
Description
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.